Taiwan white biotechnology Tangbao and Gubao are selected into the cross strait drug R & D cooperation project

White biotech new drug not only has the successful experience in the research and development of new plant drugs, but also is worth learning from the other side Moreover, "bone treasure" and "sugar treasure" have obtained patents in mainland China, and actively launched the layout During the exhibition, Dr Zheng Jianxin, general manager of white biotechnology and new drugs, will be invited to be the moderator of the "mainland cooperation experience discussion" in the forum He will exchange views with the participating experts and talk about the layout and future of the cross-strait healthcare industry Zheng Jianxin said that under the 13th five year plan, the major health industry in the mainland will move towards the goal of narrowing the medical gap between urban and rural areas and responding to the huge demand for health care in the aging society If the two sides can cooperate to develop high-quality and affordable new drugs, medical materials and health care products, and jointly improve the medical standards of the people on both sides, there will be unlimited business opportunities Although Chinese herbal medicine is often used to treat diseases in mainland China, but the process of brewing is lack of scientific test certificate White biotechnology new drug has successfully established the model of "western medicine of new plant drugs", which is attractive to mainland China In terms of "white blood treasure injection", it is the first prescription new drug approved by the food and Drug Administration of Taiwan It extracts, separates and highly purifies Radix Astragali to make high-quality intravenous injection, ensuring safety and quality Li Chengjia, chairman of the board of directors, said that "Tangbao" and "Gubao" of white biotechnology new drugs were selected into the cross strait drug R & D cooperation project Tangbao is used for the treatment of diabetic nephropathy At present, it is planned to study biomarker in patients with special conditions In the second phase of human clinical trial, "Gubao", which is used for the treatment of osteoporosis, found that there is no common side effect of commercially available drugs for the treatment of osteoporosis; after successful development, it is expected to break through the bottleneck of Western medicine for the treatment of osteoporosis in the future Both drugs have been approved for patent in mainland China, which also shows white's intention of new biotech drugs in the mainland market.